Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App




Quantitative Fetomaternal Hemorrhage Assessed with Lab Tests

By LabMedica International staff writers
Posted on 06 Oct 2016
Fetomaternal hemorrhage (FMH) assessment is usually used to determine anti-D immunoglobulin dose in postpartum prophylaxis of the hemolytic disease of the fetus and newborn (HDFN).

In maternal blood, fetal red blood cells (RBCs) can be identified due to the differences between them and adult RBCs and these are fetal hemoglobin (HbF) presence, lack of the carbonic anhydrase (CA), and the presence of particular group antigen.

Scientists at the Centre of Postgraduate Medical Education (Warsaw, Poland) collected blood samples on EDTA as follows: 20 RhD-negative blood donors samples to evaluate test specificity, 18 RhD-negative blood donors and 18 RhD-positive cord blood samples to prepare mixtures imitating FMH from 0.1% to 5%, and 14 weak D blood donors samples to evaluate test specificity with anti-D antibodies and to perform 20 suspensions with the RBCs of 10 RhD-positive blood donors. More...
Blood samples from 98 women were tested: 74 from women just before labor and in 1 to 2 hours after it, 10 only before childbirth, including five before 40 weeks of pregnancy, due to fetal anemia, and 14 only after labor.

The amount and parameters of RBCs were measured with the COULTER AcT diff/diff2 Hematology Analyzer (Beckman Coulter, Brea, CA, USA) to prepare RBCs mixtures with the known percentage of fetal cells. The team used three flow cytometry methods including Antigen D staining, Hemoglobin F (HbF) staining and HbF and carbonic anhydrase (CA) staining. The flow cytometer was calibrated correctly and in all samples, 50,000 RBCs were analyzed using FACSCanto II and FACSDiva software (Becton, Dickinson and Company, Franklin Lakes, NJ, USA). The scientists also carried out Kleihauer–Betke test (KBT), which is based on HbF resistance to acid elution while HbA is removed from cells.

The hematologists found that in all artificial mixtures with known concentrations, FCTs and KBT with counting 10,000 RBCs had similar satisfying sensitivity and specificity. KBT with counting 2000 RBCs had to be disqualified because of significant discrepancies between expected and measured values of FMH. The test procedure with anti-D was easier and shorter than the remaining tests, but it can be only used for FMH assessment in RhD-negative mothers with RhD-positive newborns. In one clinical sample, it was impossible to distinguish fetal RBCs from maternal F cells in KBT and FC with anti-HbF but other tests were useful.

The authors concluded that the methods that use flow cytometry and anti-HbF, anti-D, and anti-HbF + anti-CA antibodies, as well as microscopic Kleihauer–Betke test detecting HbF-positive blood cells, with counting 10 000 of RBCs, have similar satisfying sensitivity and specificity. In the four tests, correlation between expected and obtained results was appropriate. Each test had some advantage and limitation in any clinical situation. Therefore, it is best to have opportunity to perform two or three assays in the laboratory. The study was published in the August 2016 issue of the International Journal of Laboratory Hematology.

Related Links:
Centre of Postgraduate Medical Education
Beckman Coulter
BD

New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
New
HPV Test
Allplex HPV28 Detection
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Roche’s CE-Marked Elecsys pTau217 blood test is a single‑assay blood test measures phosphorylated tau 217, an indicator of amyloid pathology and a hallmark of Alzheimer’s disease (image credit: Shutterstock)

Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection

Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more

Molecular Diagnostics

view channel
Image: Clarifying tumor microenvironment features and cancer-cell programs linked to treatment response could provide earlier insight into triple-negative breast cancer therapy (image credit: Shutterstock)

Gene Panel Shows Promise for Predicting Chemotherapy Response in TNBC

Triple-negative breast cancer (TNBC) is an aggressive subtype commonly treated with chemotherapy, yet outcomes vary widely among patients. Understanding the tumor features that drive this variability remains... Read more

Microbiology

view channel
Image: The initiative combines epidemiological and microbiological data with whole-genome sequencing to characterize circulating hospital lineages and resistance determinants (image credit: Shutterstock)

Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals

Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.